Bioxyne LimitedASX: BXN

BLS to Manufacture and Distribute Curaleaf International MID

· Issued by Bioxyne Limited

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The device is the first EU Class IIa medical device designed for use with medical cannabis liquid inhalants, set to launch in November. This partnership is expected to create a new recurring revenue stream for Bioxyne, contributing significantly to their financial guidance for the upcoming fiscal year. The announcement highlights Bioxyne's commitment to expanding access to regulated inhalation technology in Australia.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Bioxyne Limited on 6ix

Earlier from Bioxyne

Later from Bioxyne

All Bioxyne news releases